Lyell Immunopharma

Lyell Immunopharma

生物技术研究

South San Francisco,CA 17,711 位关注者

A clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer

关于我们

Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.

网站
https://www.lyell.com
所属行业
生物技术研究
规模
201-500 人
总部
South San Francisco,CA
类型
上市公司
创立
2018

地点

  • 主要

    201 Haskins Way

    US,CA,South San Francisco,94080

    获取路线
  • 500 Fairview Ave N

    Suite 560

    US,Washington,Seattle,98109

    获取路线
  • 2525 223rd St SE

    US,Washington,Bothell,98021

    获取路线

Lyell Immunopharma员工

动态

相似主页

查看职位

融资

Lyell Immunopharma 共 2 轮

上一轮

C 轮

US$492,999,957.00

Crunchbase 上查看更多信息